Navigation Links
ViroPharma Announces First Quarter 2013 Financial Results
Date:5/1/2013

="http://www.viropharma.com/Products.aspx">http://www.viropharma.com/Products.aspx; the prescribing information for other countries can be found at www.viropharma.com

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2013, forecasted future tax rates, our ability to continue to successfully commercialize our products in the United States and Europe, the timing and results of anticipated events in our clinical development programs; and our ability to identify and execute upon business development opportunities.

Our actual results may vary depending on a variety of factors, including:

  • our ability to continue to identify and retain prophylaxis Cinryze patients in the United States and Europe at the rate we anticipate, the total number of potential prophylaxis Cinryze patients in the United States and Europe and our market share of HAE patients in the United States and Europe;
  • the size of the market, future growth potential and market share for Buccolam and Plenadren in Europe;
  • the availability of sufficient third party payer reimbursement for each of our products in the United States and Europe;
  • fluctuations in wholesaler and SP order patterns and inventory levels;
  • competition from the approval of products which are currently marketed f
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Participate in Two December Healthcare Investor Conferences
    2. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
    3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    4. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    5. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
    6. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
    7. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
    8. WuXi PharmaTech Announces Third-Quarter 2011 Results
    9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
    10. Spherix Announces Third Quarter Financial Results
    11. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... (PRWEB) October 30, 2014 Whitehouse Laboratories ... its ICH Stability Testing and Package Test Capacity. Responding ... centers on a dramatic increase in environmental chamber storage ... stability, storage and aging samples to be securely held ... this major capital expenditure has already taken place with ...
    (Date:10/30/2014)... 30, 2014 Isis Pharmaceuticals, Inc. (NASDAQ: ... management will present a company overview at the Nomura Biotechnology ... in Boston, MA. A ... "Investors & Media" section of the Company,s website, www.isispharm.com ... within 48 hours and will be archived for a limited ...
    (Date:10/30/2014)... of the key challenges in the development of quantum ... , In a paper published today (28 October) in ... show how to make a new type of flexibly ... such as high-precision sensors and specialised superfast computers, often ... the methods for trapping these tiny particles are hugely ...
    (Date:10/27/2014)... 2014 The new research report, ... & Medium), Sub-type (Primary & Secondary), and End-User ... Transportation & Power Generation) - Trends and Forecasts ... with analysis and forecasting of the market size. ... with 52 Figures spread through 146 Pages and ...
    Breaking Biology Technology:Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4
    ... July 15 Amsterdam,Molecular Therapeutics (Euronext: AMT), a ... announced the start of a collaboration with St. ... the development,of a gene therapy treatment for Hemophilia ... commercial rights to the final product. The,combination of ...
    ... A report published in the July 8 issue of ... Sciences ( PNAS ) is the first to ... of tiny nanoclusters of metallic gold. The study, which ... the work of researchers at four universities on two ...
    ... HealthSonix, Inc.,(Pink Sheets: HSXI)(FWB:H7S) today announced that ... purchased two wholly owned,subsidiaries of HealthSonix, Inc. ... "Selling the two operating companies to Innovative ... the companies to,resume full operations and get ...
    Cached Biology Technology:AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 2AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 3AMT Starts Collaboration With St. Jude Children's Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy 4Study reveals principles behind stability and electronic properties of gold nanoclusters 2Study reveals principles behind stability and electronic properties of gold nanoclusters 3Study reveals principles behind stability and electronic properties of gold nanoclusters 4HealthSonix Sells Operating Subsidiaries to Innovative Health Sciences 2
    (Date:10/29/2014)... the international Cancer Genomics of the Kidney consortium ... kidney cancer and exposure to aristolochic acid, an ... in Nature Communications , have important implications ... than 140,000 people every year, and in Central ... part of the International Cancer Genome Consortium (ICGC), ...
    (Date:10/28/2014)... Scientists from North America, Europe and China have published ... Academy of Sciences that reveals important details about ... our planet., From strange and exotic algae, mosses, ferns, ... the grains and vegetables we eat and the ornamental ... shares over a billion years of history., "Our study ...
    (Date:10/28/2014)... Technological University Singapore (NTU Singapore) will be building ... renewable energy sources. , The first in the ... the integration of solar, wind, tidal-current, diesel, storage ... operate well together. , To be built under ... initiative, the hybrid micro-grid will be located offshore ...
    Breaking Biology News(10 mins):Kidney cancer in Central Europe 2New study uses DNA sequences to look back in time at key events in plant evolution 2New study uses DNA sequences to look back in time at key events in plant evolution 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
    ... condition that can appear after breast cancer surgery, ... survivors. Although lymphedema can cause lifelong swelling in ... no national standard of diagnosis or care. Now, ... Lymphedema Framework Project (ALFP), a national, multi-disciplinary collaboration ...
    ... Inc. has obtained a non-exclusive license to make ... developed at Case Western Reserve University,s Department of ... Center in Cleveland. The ... based in Indiana, Pa., rights to intramuscular recording ...
    ... Food packaging and other disposable plastic items could soon be ... new sugar-based polymer. The degradable polymer is made ... crops such as fast-growing trees and grasses, or renewable biomass ... at Imperial College London by a team of Engineering and ...
    Cached Biology News:Researchers develop standard of care for breast cancer survivors with lymphedema 2Compostable plastics have a sweet ending 2
    ... Johnstone and M.W. Turner ... describes step-by-step methods for ... relevant molecules, the use ... specific analytical probes and ...
    Request Info...
    LabFax: Immunochemistry...
    Edited by P.J. Delves (1997) An up-to-date review of antibody-raising technologies, this volume provides researchers with immediate access to the protocols they require every day....
    Biology Products: